Movement Alert｜INNOVENT BIO Intraday Rise 3.06% in Regular Trading, IBI3003 data and a higher target price supported sentiment

Market Focus10-23

On October 23, INNOVENT BIO rose 3.06% intraday in Regular Trading, trading at HK$84.15, with turnover of HK$1.103 billion.

The move coincided with continued market digestion of the company’s recently disclosed Phase I data for IBI3003 in relapsed or refractory multiple myeloma, alongside a broker target price increase to HK$138.63 with a Buy rating maintained.

Background details show IBI3003, a BCMA x GPRC5D x CD3 trispecific T-cell engager, delivered an objective response rate of 84.6% in 102 patients, with rates above complete response and above very good partial response at 42.3% and 57.7%, respectively. The asset has already advanced into a Phase III registrational study in China, reinforcing expectations around INNOVENT BIO’s hematology pipeline and near-term development visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment